# Circular PCR as an efficient and precise umbrella of methods for the generation of circular dsDNA with staggered nicks: Mechanism and types

**Authors:** Pedro Ferro-Gallego, Antón Vila-Sanjurjo, Andrea Katherine Valderrama Pereira, Gonzalo Porres Pérez, Lourdes Domínguez-Gerpe

PMC · DOI: 10.1093/biomethods/bpae051 · 2024-08-12

## TL;DR

CiPCR is a new DNA amplification method that efficiently creates circular DNA with staggered nicks, useful for various molecular cloning tasks.

## Contribution

The novel CiPCR technique and its two types (Type I and Type II) are introduced, offering a versatile solution for molecular cloning challenges.

## Key findings

- CiPCR generates stable circular dsDNA with staggered nicks through continuous elongation from hybridized DNA fragments.
- Type I CiPCR allows all four 3′-ends to prime amplification, while Type II CiPCR only allows two.
- CiPCR is effective for resolving common molecular cloning challenges like insertions, deletions, and mutations.

## Abstract

Here, we introduce the highly versatile circular polymerase chain reaction (CiPCR) technique, propose a mechanism of action, and describe a number of examples demonstrating the versatility of this technique. CiPCR takes place between two fragments of dsDNA with two homologous regions, as long as one of the fragments carries said regions at its 3′- and 5′-ends. Upon hybridization, elongation by a polymerase occurs from all 3′-ends continuously until a 5′-end is reached, leading to stable circular dsDNA with staggered nicks. When both dsDNA fragments carry the homology at their 3′- and 5′-ends (Type I CiPCR), all four 3′-ends effectively prime amplification of the intervening region and CiPCR products can function as template during the reaction. In contrast, when only one of the two dsDNA fragments carries the homologous regions at its 3′- and 5′-ends and the other carries such regions internally (Type II CiPCR), only two 3′-ends can be amplified and CiPCR products possess no template activity. We demonstrate the applicability of both CiPCR types via well-illustrated experimental examples. CiPCR is well adapted to the quick resolution of most of the molecular cloning challenges faced by the biology/biomedicine laboratory, including the generation of insertions, deletions, and mutations.

## Full-text entities

- **Genes:** Tmprss15 (transmembrane protease, serine 15) [NCBI Gene 19146] {aka Entk, Prss7}, UQCC6 (ubiquinol-cytochrome c reductase complex assembly factor 6) [NCBI Gene 728568] {aka BR, BRAWNIN, C12orf73}, Brca1 (breast cancer 1, early onset) [NCBI Gene 12189], SLC16A1 (solute carrier family 16 member 1) [NCBI Gene 6566] {aka HHF7, MCT, MCT1, MCT1D}, ABCB6 (ATP binding cassette subfamily B member 6 (LAN blood group)) [NCBI Gene 10058] {aka ABC, LAN, MTABC3, PRP, umat}, KRT32 (keratin 32) [NCBI Gene 3882] {aka HA2, HKA2, KRTHA2, hHa2}, F2R (coagulation factor II thrombin receptor) [NCBI Gene 2149] {aka CF2R, HTR, PAR-1, PAR1, TR}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, SP1 (Sp1 transcription factor) [NCBI Gene 6667], Thrb (thyroid hormone receptor beta) [NCBI Gene 21834] {aka Nr1a2, T3R[b], T3Rbeta, Thrb1, Thrb2, c-erbAbeta}, SLC16A2 (solute carrier family 16 member 2) [NCBI Gene 6567] {aka AHDS, DXS128, DXS128E, MCT 7, MCT 8, MCT7}, KRT31 (keratin 31) [NCBI Gene 3881] {aka HA1, Ha-1, KRTHA1, hHa1}, THRB (thyroid hormone receptor beta) [NCBI Gene 7068] {aka C-ERBA-2, C-ERBA-BETA, ERBA2, GRTH, NR1A2, PRTH}, Oprm1 (opioid receptor, mu 1) [NCBI Gene 18390] {aka M-OR-1, MOP-R, MOR-1, MOR-1O, Oprm, mor}, RCAN2 (regulator of calcineurin 2) [NCBI Gene 10231] {aka CSP2, DSCR1L1, MCIP2, ZAKI-4, ZAKI4}, CHKA (choline kinase alpha) [NCBI Gene 1119] {aka CHK, CK, CKI, EK, NEDMIMS}, TBP (TATA-box binding protein) [NCBI Gene 6908] {aka GTF2D, GTF2D1, HDL4, SCA17, TBP1, TFIID}, H4C16 (H4 histone 16) [NCBI Gene 121504] {aka H4-16, H4/p, HIST4H4}, AKAP13 (A-kinase anchoring protein 13) [NCBI Gene 11214] {aka AKAP-13, AKAP-Lbc, ARHGEF13, BRX, HA-3, Ht31}, PCBP1 (poly(rC) binding protein 1) [NCBI Gene 5093] {aka HEL-S-85, HNRPE1, HNRPX, hnRNP-E1, hnRNP-X}, KRT34 (keratin 34) [NCBI Gene 3885] {aka HA4, Ha-4, K34, KRTHA4, hHa4}, Pcbp1 (poly(rC) binding protein 1) [NCBI Gene 23983] {aka WBP17, [a]CP-1, alphaCP-1, hnRNP E1, hnRNP-E1}, KLF9 (KLF transcription factor 9) [NCBI Gene 687] {aka BTEB, BTEB1}
- **Diseases:** LIC (MESH:D064129), cancer (MESH:D009369)
- **Chemicals:** NaCL (MESH:D012965), 2H (MESH:D003903), glycerol (MESH:D005990), DpnI (-), Hepes (MESH:D006531), PVDF (MESH:C024865), DTT (MESH:D004229), sodium acetate (MESH:D019346), HCl (MESH:D006851), ice (MESH:D007053), paraformaldehyde (MESH:C003043), polyhistidine (MESH:C033223), EDTA (MESH:D004492), agarose (MESH:D012685), arabinose (MESH:D001089), water (MESH:D014867), geneticin (MESH:C010680), polyacrylamide (MESH:C016679), CY5 (MESH:C085321), SDS (MESH:D012967), PBS (MESH:D007854), luciferin (MESH:D000090562), DMSO (MESH:D004121), tween 20 (MESH:D011136), Si (MESH:D012825), Lipofectamine (MESH:C086724), Triton X-100 (MESH:D017830), imidazole (MESH:C029899), Ni (MESH:D009532), iron (MESH:D007501), ethanol (MESH:D000431), MgCl2 (MESH:D015636), FAM (MESH:C031179), leupeptin (MESH:C032854), TRIzol (MESH:C411644), ampicillin (MESH:D000667), DAPI (MESH:C007293)
- **Species:** Homo sapiens (human, species) [taxon 9606], Pectobacterium carotovorum (species) [taxon 554], Escherichia coli BL21 (strain) [taxon 511693], Mus musculus (house mouse, species) [taxon 10090], Escherichia coli (E. coli, species) [taxon 562]
- **Mutations:** c.1_123del, p.1_26del, rs104894931, c.1_2582del, L512P, S107P, T to G base change at position 14, pr.-991_-987del, pr.-993_-985del, pr.-303_-295del, T > G
- **Cell lines:** COS-7 — Chlorocebus aethiops (Green monkey), Transformed cell line (CVCL_0224), H4 — Macaca fascicularis (Crab-eating macaque), Induced pluripotent stem cell (CVCL_JF98), GST — Homo sapiens (Human), Transformed cell line (CVCL_B2YD), NCI H-460 — Homo sapiens (Human), Lung large cell carcinoma, Cancer cell line (CVCL_0459), p2GUS-10H — Homo sapiens (Human), Hepatitis C infection, Cancer cell line (CVCL_0C53), -10H — Mus musculus (Mouse), Hybridoma (CVCL_C4R4), r-10H — Mus musculus (Mouse), Mouse adrenal cortical carcinoma, Cancer cell line (CVCL_5G19), SH-SY5Y — Homo sapiens (Human), Neuroblastoma, Cancer cell line (CVCL_0019), A-172 — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_0131), BALB/c — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0184)

## Figures

13 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11319657/full.md

---
Source: https://tomesphere.com/paper/PMC11319657